Multiple Sclerosis Clinical Trials in San Antonio

Showing 241-260 of 513 trials

Study of ASN003 in Subjects With Advanced Solid Tumors

NCT02961283

The study is divided into two parts. The first part of the study will test various doses of ASN003 to find out the highest safe dose to test in three specific groups. The second part of the study will test how well ASN003 can control cancer. Subjects will be enrolled into one of three groups. Group 1: metastatic or recurrent melanoma with documented BRAFV600 mutation (n=20 evaluable patients) Group 2: metastatic colorectal cancer (CRC), or advanced non-small cell lung cancer (NSCLC) with documented BRAFV600 mutation (n=14 evaluable patients) Group 3: advanced solid tumors with documented PI3K pathway alterations (PIK3CA mutation or PTEN loss) (n=14 evaluable patients)

NeoplasmsMelanomaColorectal Neoplasm+1 more

Asana BioSciences24 participantsStarted Oct 2016

Los Angeles, California, United States • Tampa, Florida, United States • Boston, Massachusetts, United States +2 more locations

COMPLETEDPhase 3< 1 mile

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03038100

This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.

Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms

Hoffmann-La Roche1,301 participantsStarted Mar 2017

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +265 more locations

Study of ASN003 in Subjects With Advanced Solid Tumors

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Multiple Sclerosis Trials in Other Cities

An Extension of the TG1101-RMS201 Trial

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Study of Diroximel Fumarate in the Real-World Setting

Dimethyl Fumarate (DMF) Observational Study

Safety Study of SEA-CD40 in Cancer Patients

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

Relative Bioavailability of LY03010 Compared to Listed Drug

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Other Conditions in San Antonio